scholarly journals New-Onset Movement Disorders Associated with COVID-19

2021 ◽  
Vol 11 (1) ◽  
pp. 26
Author(s):  
Pedro Renato P. Brandão ◽  
Talyta C. Grippe ◽  
Danilo A. Pereira ◽  
Renato P. Munhoz ◽  
Francisco Cardoso
Keyword(s):  
Movement Disorders ◽  
New Onset

scholarly journals Movement Disorders Associated With Antipsychotic Medication in People With Schizophrenia: An Overview of Cochrane Reviews and Meta-Analysis

2018 ◽  
Vol 63 (11) ◽  
pp. 730-739 ◽  
Author(s):  
Davide Martino ◽  
Vikram Karnik ◽  
Sydney Osland ◽  
Thomas R. E. Barnes ◽  
Tamara M. Pringsheim
Keyword(s):  
Systematic Reviews ◽  
Movement Disorders ◽  
Randomised Controlled Trials ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Antipsychotic Medications ◽  
Cochrane Reviews ◽  
Prevalence Estimates ◽  
Randomised Controlled ◽  
New Onset

Movement disorders associated with antipsychotic medications are relatively common, stigmatising, and potentially disabling. Their prevalence in people with psychosis who are prescribed second-generation antipsychotics (SGAs) is uncertain, as is their level of recognition by clinicinas. We conducted meta-analyses of randomised controlled trials included in the Cochrane Database of Systematic Reviews on schizophrenia and schizophrenia-like psychoses to estimate the prevalence of new-onset dystonia, akathisia, parkinsonism, and tremor with SGAs (amisulpride, asenapine, aripiprazole, clozapine, olanzapine, paliperidone, quetiapine, risperidone, L-sulpiride, and ziprasidone) approved in Canada and the UK, comparing them with haloperidol and chlorpromazine. We used a random effects model because of the heterogeneity between-studies in drug dosage and method of ascertainment of movement disorders. Our systematic search yielded 37 Cochrane systematic reviews (28 for SGAs), which generated 316 informative randomised controlled trials (243 for SGAs). With respect to SGAs, prevalence estimates ranged from 1.4% (quetiapine) to 15.3% (L-sulpiride) for dystonia, 3.3% (paliperidone) to 16.4% (L-sulpiride) for akathisia, 2.4% (asenapine) to 29.3% (L-sulpiride) for parkinsonism, and 0.2% (clozapine) to 28.2% (L-sulpiride) for tremor. Prevalence estimates were not influenced by treatment duration, the use of a flexible or fixed dosing scheme, or whether studies used validated instruments for the screening/rating of movement disorders. Overall, we found high overlap on the prevalence of new-onset movement disorders across different SGAs precribed for established psychoses. Variations in prevalence figures across antipsychotic medications were observed for the different movement disorders. Differences in pharmacological properties, such as for the dopamine D2 R association rate and serotonin 5-HT2A antagonism, could contribute to this variation.

scholarly journals An unusual presentation of encephalitis which mimicked generalised tetanus

2021 ◽  
Vol 8 (7) ◽  
pp. 1319
Author(s):  
Anushree M. Benny ◽  
Rajendra Prasad Nagar ◽  
Gautam Lal Nagori
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Movement Disorders ◽  
Viral Encephalitis ◽  
Central Nervous System Infection ◽  
Muscle Spasm ◽  
Temporal Lobes ◽  
Csf Analysis ◽  
Intravenous Acyclovir ◽  
New Onset

Movement disorders are frequent mimickers of more severe neurological presentations, whenever it is diagnosed one should suspect a central nervous system infection as an underlying cause. A 11 year old girl presented in casuality with intermittent generalised muscle spasm, clear sensorium, trismus and risus sardonicus. Initially managed as a case of tetanus, rapid resolution of spasms made suspicion of encephalitis as underlying cause of dystonia which mimicked tetanus. Blood investigation and CSF analysis were normal. CECT brain showed hyper dense lesions bilateral temporal lobes suggestive of viral encephalitis. Child was managed with intravenous acyclovir and dexamethasone after which child improved considerably. Acute dystonia is a close mimicker of tetanus. Any patient presenting with new onset movement disorder should be investigated for central nervous system infection even though it has been reported as a rare cause for the same.

Drug-Induced Movement Disorders

2015 ◽  
Vol 25 (2) ◽  
pp. 70-77
Author(s):  
Amy Lustig ◽  
Cesar Ruiz
Keyword(s):  
Movement Disorders ◽  
Medical Management ◽  
Disease Process ◽  
Underlying Disease ◽  
Extrapyramidal Symptoms ◽  
Drug Induced ◽  
General Overview ◽  
Management Approaches ◽  
Broad Understanding ◽  
Underlying Disease Process

The purpose of this article is to present a general overview of the features of drug-induced movement disorders (DIMDs) comprised by Parkinsonism and extrapyramidal symptoms. Speech-language pathologists (SLPs) who work with patients presenting with these issues must have a broad understanding of the underlying disease process. This article will provide a brief introduction to the neuropathophysiology of DIMDs, a discussion of the associated symptomatology, the pharmacology implicated in causing DIMDs, and the medical management approaches currently in use.

MRI Aids Diagnosis of New-Onset Afebrile Seizures

2006 ◽  
Vol 40 (2) ◽  
pp. 49
Author(s):  
DIANA MAHONEY
Keyword(s):  
Aids Diagnosis ◽  
New Onset

Valsartan May Lower Rate Of New-Onset Atrial Fib

2006 ◽  
Vol 39 (19) ◽  
pp. 1-2
Author(s):  
BRUCE JANCIN
Keyword(s):  
New Onset
Sign in / Sign up

Export Citation Format

Share Document